Director sells over $1M of Arrowhead Pharmaceuticals shares, highlighting insider transaction
Executive summary: A director of Arrowhead Pharmaceuticals sold 11,600 shares of the company for about $1 million. Insider sales can influence investor sentiment and are watched for potential signals about executive confidence in the firm’s prospects.
Who is involved: Arrowhead Pharmaceuticals director (unnamed) and Arrowhead Pharmaceuticals
Likely next: Market participants may watch for additional insider filings or company guidance; the stock could experience short‑term price pressure.
On September 6, 2026, a director of Arrowhead Pharmaceuticals reported the sale of 11,600 shares for approximately $1 million, as disclosed in a Form 4 filing. The transaction represents a small fraction of the director’s holdings and is reported in compliance with SEC insider‑trading rules. Such sales are routinely monitored by investors for signals about executive confidence, though a single sale does not necessarily indicate a change in company outlook.
Timeline
- — Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million (Yahoo Finance)
Analysis — what this means
Sectors affected
- biotechnology
- pharmaceuticals
Regulatory implications
- SEC Rule 10b-5 requires disclosure of insider transactions via Form 4 within two business days
Sources
Related cases
- Fosun Pharma launches up to HK$1 billion H‑share buyback to bolster shareholder returns
- Unusual Machines CFO Brian Hoff sold 11,413 shares, signaling potential insider sentiment
- Thai team’s drone‑mounted bionic eagle‑claw gripper for disaster relief reaches the Lancang‑Mekong science finals, spotlighting regional rescue‑robotics advances
- Sabotage attack on German electricity substation raises security concerns for regional power supply
- The US Mint's release of a $1 coin bearing Donald Trump's portrait creates a new niche in the presidential memorabilia market, potentially boosting numismatic sales and signaling heightened political branding in currency
- Greenberg Traurig strengthens its litigation practice with the addition of former federal prosecutor David M. Herzog